BioSpace News Archive

ASLAN Pharmaceuticals announced financial results for the fourth quarter and full year ended December 31, 2021, and provided an update on recent corporate activities.

Visby Medical™, a leading medical diagnostic company, announced that it has received an additional $25.5M in federal funding to develop and validate an at-home combination Flu-Covid test from the Biomedical Advanced Research and Development Authority.

Sun Pharmaceutical Industries Limited today announced that the company’s U.S. subsidiary presented data from two pivotal Phase 3 clinical trials of WINLEVI (clascoterone) cream 1% for the topical treatment of acne vulgaris (acne).

Heat Biologics,Inc., a clinical-stage biopharmaceutical company focused on developing novel biodefense assets and first-in-class therapies to modulate the immune system, unveiled enhanced allogeneic cell therapy manufacturing capabilities through its Scorpion Biological Services subsidiary.

Vertex Pharmaceuticals (Canada) Incorporated (NASDAQ: VRTX) today announced that Health Canada has granted Marketing Authorization for the expanded use of PrKALYDECO® (ivacaftor) in patients from 4 months to 18 years of age and weighing at least 5 kg with the R117H mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced changes to its Board of Directors.

Broncus Medical (02216HK), Inc., today announced online publication in the Respirology journal of a global, multicenter study demonstrating the effectiveness of the company’s Archimedes® Virtual Bronchoscopic Navigation (VBN) System in guiding the sampling of peripheral pulmonary lesions.

Therapeutic Solutions International announced today the execution of a purchase agreement covering sponsorship and leadership of the FDA cleared Phase III pivotal trial assessing JadiCell adult stem cells for treatment of COVID-19 associated lung failure.

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended Janssen Pharmaceutica NV’s marketing authorization of CARVYKTI®.

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the Centers for Medicare & Medicaid Services (CMS) has approved transitional pass-through status for ZYNRELEF.